gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ALNYHealthcarePharmaceuticals

Alnylam Pharmaceuticals, Inc. (ALNY)

$161.08+0.74%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$161.08▼ 61.96% in range
Nov 4, 2025Low $158.00 · High $473.29Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Alnylam Pharmaceuticals closed at $161.08 on Nov 4, up 0.74%, within 1.9% of its 52-week closing low. Volume of 3.6M shares was 1.48× its 20-day average (above normal).

Split-adjusted performance: -28.1% over one month, -46.8% over six months, -62.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.46B, up 16.7% from a year earlier, with a net margin of 148.6%.

Short interest was 6.6M shares at the Oct 15 settlement, down 14.8% from the prior report (4.9% of float, 5.1 days to cover).

Market cap$21.57B133.9M shares
Revenue · quarter$1.46B+16.7% YoY
Diluted EPS$15.72+634.6% YoY
P/E · TTM7.9×P/S 4.3×
Net margin148.6%Gross 75.2%
Dividend yieldNone
52-week range158.00 – 473.29−66.0% from high
Volume3.6M1.48× 20-day avg
Volatility · 60d72.8%Annualised
Short % of float4.9%5.1 days to cover
Net cash$2.57BCash $3.59B
Next earnings—Not scheduled
Split-adjusted performance
1W −30.7%1M −28.1%3M −25.5%6M −46.8%YTD −59.5%1Y −62.9%3Y +6.4%5Y −15.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum28
Revenue growth63
Net margin98
Value (low P/E)76
Size96

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short6.6M−14.8% vs prior
Days to cover5.1Settled Oct 15
% of float4.9%
Short vol. 10d27.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ALNYAlnylam Pharmaceuticals$161.08+0.74%−46.8%+16.7%148.6%7.9$21.57B
VTRSViatris$19.22+1.59%+20.5%+4.9%−3.2%—$22.08BCompare
INSMInsmed$110.00+5.32%−19.8%+268.4%−19.1%—$24.13BCompare
UTHRUnited Therapeutics$608.49+1.19%+2.0%−1.9%42.5%19.9$26.10BCompare
ROIVRoivant Sciences$38.23+6.08%+32.7%−33.5%−13164.8%—$27.61BCompare
RPRXRoyalty Pharma$67.56+1.75%+33.2%+16.5%2.7%36.9$30.08BCompare
JAZZJazz Pharmaceuticals$234.66+2.14%+2.7%+10.4%−38.9%74.0$15.23BCompare
BBIOBridgeBio Pharma$77.89+5.21%+14.4%+192.6%−23.5%—$15.17BCompare
SMMTSummit Therapeutics$16.17+2.34%−9.4%———$12.90BCompare

News about Alnylam Pharmaceuticals

All news →
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesZacks Investment Research · 6d ago▼ NegativeAlnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research · Oct 22, 2026▲ PositiveAlnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?The Motley Fool · Oct 21, 2026▲ PositiveSecurities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlobeNewswire Inc. · Oct 5, 2026▼ Negative18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.The Motley Fool · Sep 28, 2026▲ Positive

Quick answers

What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
What is ALNY's market cap?
$21.57B, based on the Nov 4 close of $161.08.
What is ALNY's P/E ratio?
7.9× trailing-twelve-month earnings of $2.72B.
Does Alnylam Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ALNY is sold short?
6.6M shares, 4.9% of float, as of Oct 15, 2026.
What sector is ALNY in?
Healthcare, in the Pharmaceuticals industry.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

HQ: Cambridge, MA2,500 employeesListed May 28, 2004alnylam.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology